サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1434555

抗凝固剤市場：投与経路、抗凝固薬、薬剤クラス別、用途別-2024～2030年の世界予測

Anticoagulants Market by Route of Administration (Injectable Anticoagulants, Oral Anticoagulants), Anticoagulant Drug (Betrixaban, Dabigatran, Edoxaban or Rivaroxaban), Drug Class, Application - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 182 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗凝固剤市場：投与経路、抗凝固薬、薬剤クラス別、用途別-2024～2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗凝固剤市場規模は2023年に402億米ドルと推計され、2024年には442億4,000万米ドルに達し、CAGR 10.14%で2030年には790億7,000万米ドルに達すると予測されます。

抗凝固剤の世界市場

主な市場の統計
基準年[2023］ 402億米ドル
予測年[2024] 442億4,000万米ドル
予測年 [2030] 790億7,000万米ドル
CAGR（%） 10.14%
抗凝固剤 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗凝固剤市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、抗凝固剤市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-抗凝固剤市場の市場規模および予測は？

2-抗凝固剤市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-抗凝固剤市場における技術動向と規制の枠組みは？

4-抗凝固剤市場における主要ベンダーの市場シェアは？

5-抗凝固剤市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 静脈血栓塞栓症および心血管障害の有病率の増加
      • 抗凝固管理プログラムの数が増加
      • 新しい口頭抗凝固剤の受け入れが増加
    • 抑制要因
      • 医薬品の投与量と臨床承認に関する厳しい規制
    • 機会
      • 新しい抗凝固療法のイントロダクションと研究開発投資の増加
      • AIとMLを使用して抗凝固制御を予測する
    • 課題
      • 経口抗凝固剤の使用に伴う副作用と合併症
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 抗凝固剤市場：投与経路別

  • 注射用抗凝固剤
  • 経口抗凝固剤

第7章 抗凝固剤市場：抗凝固薬別

  • ベトリキサバン
  • ダビガトラン
  • エドキサバンまたはリバーロキサバン
  • エリキュース

第8章 抗凝固剤市場：薬剤クラス別

  • DTI
  • 第XA因子阻害剤
  • ヘパリン
  • ビタミンK拮抗薬

第9章 抗凝固剤市場：用途別

  • 心房細動と心臓発作
  • 深部静脈血栓症
  • 肺塞栓症
  • 脳卒中

第10章 南北アメリカの抗凝固剤市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の抗凝固剤市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの抗凝固剤市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第14章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Akebia Therapeutics, Inc.
    • Aspen Pharmacare Holdings Limited
    • AstraZeneca PLC
    • Athenex, Inc.
    • Bayer AG
    • C.H. Boehringer Sohn AG & Ko. KG
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • Johnson & Johnson
    • LEO Pharma A/S
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
  • 主要な製品ポートフォリオ

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTICOAGULANTS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTICOAGULANTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTICOAGULANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTICOAGULANTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTICOAGULANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTICOAGULANTS MARKET DYNAMICS
  • FIGURE 7. ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 8. ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2023 VS 2030 (%)
  • FIGURE 10. ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 12. ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ANTICOAGULANTS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. ANTICOAGULANTS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTICOAGULANTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTICOAGULANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 6. ANTICOAGULANTS MARKET SIZE, BY INJECTABLE ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTICOAGULANTS MARKET SIZE, BY ORAL ANTICOAGULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 9. ANTICOAGULANTS MARKET SIZE, BY BETRIXABAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTICOAGULANTS MARKET SIZE, BY DABIGATRAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTICOAGULANTS MARKET SIZE, BY EDOXABAN OR RIVAROXABAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTICOAGULANTS MARKET SIZE, BY ELIQUIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 14. ANTICOAGULANTS MARKET SIZE, BY DTIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTICOAGULANTS MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTICOAGULANTS MARKET SIZE, BY HEPARIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTICOAGULANTS MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTICOAGULANTS MARKET SIZE, BY ATRIAL FIBRILLATION & HEART ATTACK, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTICOAGULANTS MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTICOAGULANTS MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. ANTICOAGULANTS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY ANTICOAGULANT DRUG, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. ANTICOAGULANTS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 192. ANTICOAGULANTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. ANTICOAGULANTS MARKET LICENSE & PRICING
目次
Product Code: MRR-4358BACA80C2

[182 Pages Report] The Anticoagulants Market size was estimated at USD 40.20 billion in 2023 and expected to reach USD 44.24 billion in 2024, at a CAGR 10.14% to reach USD 79.07 billion by 2030.

Global Anticoagulants Market

KEY MARKET STATISTICS
Base Year [2023] USD 40.20 billion
Estimated Year [2024] USD 44.24 billion
Forecast Year [2030] USD 79.07 billion
CAGR (%) 10.14%
Anticoagulants Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anticoagulants Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anticoagulants Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anticoagulants Market, highlighting leading vendors and their innovative profiles. These include Akebia Therapeutics, Inc., Aspen Pharmacare Holdings Limited, AstraZeneca PLC, Athenex, Inc., Bayer AG, C.H. Boehringer Sohn AG & Ko. KG, Eisai Co., Ltd., Eli Lilly and Company, Johnson & Johnson, LEO Pharma A/S, Novartis AG, Pfizer Inc., Sanofi S.A., Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Anticoagulants Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Route of Administration
    • Injectable Anticoagulants
    • Oral Anticoagulants
  • Anticoagulant Drug
    • Betrixaban
    • Dabigatran
    • Edoxaban or Rivaroxaban
    • Eliquis
  • Drug Class
    • DTIs
    • Factor XA Inhibitors
    • Heparin
    • Vitamin K Antagonists
  • Application
    • Atrial fibrillation & Heart Attack
    • Deep Vein Thrombosis
    • Pulmonary Embolism
    • Stroke
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Anticoagulants Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anticoagulants Market?

3. What are the technology trends and regulatory frameworks in the Anticoagulants Market?

4. What is the market share of the leading vendors in the Anticoagulants Market?

5. Which modes and strategic moves are suitable for entering the Anticoagulants Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Anticoagulants Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of venous thromboembolism and cardiovascular disorders
      • 5.1.1.2. Rising number of anticoagulation stewardship programs
      • 5.1.1.3. Increasing acceptance of novel oral anticoagulants
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations related to drug dosage and clinical approvals
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel anticoagulation therapeutics and increasing R&D investments
      • 5.1.3.2. Use of AI and ML to predict anticoagulation control
    • 5.1.4. Challenges
      • 5.1.4.1. Side-effects and complications associated with the usage of oral anticoagulants
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Anticoagulants Market, by Route of Administration

  • 6.1. Introduction
  • 6.2. Injectable Anticoagulants
  • 6.3. Oral Anticoagulants

7. Anticoagulants Market, by Anticoagulant Drug

  • 7.1. Introduction
  • 7.2. Betrixaban
  • 7.3. Dabigatran
  • 7.4. Edoxaban or Rivaroxaban
  • 7.5. Eliquis

8. Anticoagulants Market, by Drug Class

  • 8.1. Introduction
  • 8.2. DTIs
  • 8.3. Factor XA Inhibitors
  • 8.4. Heparin
  • 8.5. Vitamin K Antagonists

9. Anticoagulants Market, by Application

  • 9.1. Introduction
  • 9.2. Atrial fibrillation & Heart Attack
  • 9.3. Deep Vein Thrombosis
  • 9.4. Pulmonary Embolism
  • 9.5. Stroke

10. Americas Anticoagulants Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Anticoagulants Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Anticoagulants Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Akebia Therapeutics, Inc.
    • 14.1.2. Aspen Pharmacare Holdings Limited
    • 14.1.3. AstraZeneca PLC
    • 14.1.4. Athenex, Inc.
    • 14.1.5. Bayer AG
    • 14.1.6. C.H. Boehringer Sohn AG & Ko. KG
    • 14.1.7. Eisai Co., Ltd.
    • 14.1.8. Eli Lilly and Company
    • 14.1.9. Johnson & Johnson
    • 14.1.10. LEO Pharma A/S
    • 14.1.11. Novartis AG
    • 14.1.12. Pfizer Inc.
    • 14.1.13. Sanofi S.A.
    • 14.1.14. Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
    • 14.1.15. Teva Pharmaceutical Industries Ltd.
    • 14.1.16. Viatris Inc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing